The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme, which aims to transform pioneering science into therapies. It was founded in 2015 as a new paradigm for an academic Institution, based on bridging the gap between academia and Industry. The research institute opened in summer 2019 in the new Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, providing a physical hub for these cross-sector collaborations. We have also built a global research community of 80 affiliated organisations working across academia and industry, with Cambridge providing a centre of expertise.
The Institute was co-founded by Tony Kouzarides and Jonathan Milner. The therapeutics concept and mission was developed following the establishment of the Milner Therapeutics Consortium by Tony Kouzarides. Jonathan Milner is a benefactor to the building of the Research Institute, which bears his name. Tony and Jonathan are also co-founders of Abcam plc, an antibody reagents provider based in Cambridge.
Our mission is to transform pioneering science into therapies by catalysing partnerships between academia and industry
The Milner Therapeutics Institute is led by its Director Tony Kouzarides and Deputy Director Kathryn Chapman. The institute moved from the Gurdon Institute in 2019 to the new Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, but Tony Kouzarides retains his research laboratory at the Gurdon Institute.